CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

Core Viewpoint - CytomX Therapeutics (CTMX) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for CytomX Therapeutics for the fiscal year ending December 2025 is projected at $0.10 per share, reflecting a decrease of 73.7% from the previous year [9]. - Over the past three months, analysts have raised their earnings estimates for CytomX Therapeutics by 129% [9]. Zacks Rating System - The Zacks rating system is based solely on changes in a company's earnings picture, making it a reliable tool for investors to gauge stock performance [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of CytomX Therapeutics to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].